GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1

Journal of Interferon and Cytokine Research

Volumn 29, Issue 10, 2009, Pages 645-655

  Kular, Rupinder K ^a,f   Yehiely, Fruma ^b   Kotlo, Kumar U ^c   Cilensek, Zoran M ^d   Bedi, Richa ^c   Deiss, Louis P ^e  

^a Davee Department of Neurology   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d EUROPEAN PATENT OFFICE   (Germany)

^e Harold Washington College   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 7; GAGE ANTIGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; NUCLEOPHOSMIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASE 1; CASPASE 7; CELL LINE; CELL SURVIVAL; GENE EXPRESSION; HELA CELLS; HUMANS; HYGROMYCIN B; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TIME FACTORS; TRANSFECTION;

EID: 70349661565     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0099     Document Type: Article

References (57)

1. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW. 2008. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 8:2
2. Bazhin AV, Wiedemann N, Schnolzer M, Schadendorf D, Eichmuller SB. 2007. Expression of GAGE family proteins in malignant melanoma. Cancer Lett 251(2):258-267
3. Bergstralh DT, Conti BJ, Moore CB, Brickey WJ, Taxman DJ, Ting JP. 2007. Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription. Exp Cell Res 313(1):65-76
4. Bertwistle D, Sugimoto M, Sherr CJ. 2004. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/ B23. Mol Cell Biol 24(3):985-996
5. Bowie ML, Ibarra C, Seewalt VL. 2008. IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis. Adv Exp Med Biol 617:367-374
6. Brady SN, Yu Y, Maggi LB, Jr., Weber JD. 2004. ARF impedes NPM/ B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 24(21):9327-9338
7. Chen ME, Lin SH, Chung LW, Sikes RA. 1998. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma- associated antigens. J Biol Chem 273(28):17618-17625
8. Cilensek ZM, Yehiely F, Kular RK, Deiss LP. 2002. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 1(4):380-387
9. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, Helin K, Falini B, Pelicci PG. 2005. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 25(20):8874-8886
10. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. 2002. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4(7):529-533
11. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Reme T, Goldschmidt H, Klein B. 2007. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 178(5):3307-3315
12. De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P. 1999. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 59(13):3157-3165
13. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. 1995. Identifi cation of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferoninduced cell death. Genes Dev 9(1):15-30
14. Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. 1996. Cathepsin D protease mediates programmed cell death induced by interferongamma, Fas/APO-1 and TNF-alpha. EMBO J 15(15):3861-3870
15. Egwuagu CE, Li W, Yu CR, Che Mei Lin M, Chan CC, Nakamura T, Chepelinsky AB. 2006. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25(26):3670-3679
16. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF; GIMEMA Acute Leukemia Working Party. 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254-266 (Pubitemid 40110814)
17. Gjerset RA. 2006. DNA damage, p14ARF, nucleophosmin (NPM/ B23), and cancer. J Mol Histol 37(5-7):239-251
18. Gjerstorff MF, Ditzel HJ. 2008. An overview of the GAGE cancer/ testis antigen family with the inclusion of newly identifi ed members. Tissue Antigens 71(3):187-192
19. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP. 2005. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437(7055):147-153
20. Grisendi S, Mecucci C, Falini B, Pandolfi PP. 2006. Nucleophosmin and cancer. Nat Rev Cancer 6(7):493-505
21. Grisendi S, Pandolfi PP. 2005. NPM mutations in acute myelogenous leukemia. N Engl J Med 352(3):291-292
22. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H, Taniguchi T. 1994. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 9(11):3313-3320
23. Hsu CY, Yung BY. 2000. Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int J Cancer 88(3):392-400
24. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, Hoogerbrugge PM, Coulie PG, de Vries IJ. 2007. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120(1):67-74
25. Kano A, Haruyama T, Akaike T, Watanabe Y. 1999. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 257(3):672-677
26. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, Rutka JT. 2008. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatrics 1(4):305-313
27. Kautz B, Kakar R, David E, Eklund EA. 2001. SHP1 proteintyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous cis elements in the CYBB and NCF2 genes. J Biol Chem 276(41):37868-37878
28. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N. 1997. Identifi cation and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15(11):1275-1281
29. Lambert B, Buckle M. 2006. Characterisation of the interface between nucleophosmin (NPM) and p53: potential role in p53 stabilisation. FEBS Lett 580(1):345-350
30. Lee EJ, Jo M, Park J, Zhang W, Lee JH. 2006. Alternative splicing variants of IRF-1 lacking exons 7, 8, and 9 in cervical cancer. Biochem Biophys Res Commun 347(4):882-888
31. Lee SB, Xuan Nguyen TL, Choi JW, Lee KH, Cho SW, Liu Z, Ye K, Bae SS, Ahn JY. 2008. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc Natl Acad Sci USA 105(43):16584-16589
32. Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J. 1999. Interferon regulatory factors: the next generation. Gene 237(1):1-14
33. Maratheftis CI, Bolaraki PE, Giannouli S, Kapsogeorgou EK, Moutsopoulos HM, Voulgarelis M. 2006. Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leuk Res 30(9):1177-1186
34. Nakagawa K, Yokosawa H. 2000. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur J Biochem 267(6):1680-1686
35. Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki K, Aizawa S, Ishikawa T, Katsuki M, Muto T, Taniguchi T, Tanaka N. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 13(10):1240-1245
36. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK. 2008. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 8:7
37. Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Canete A, Castel V. 2004. Minimal residual disease in neuroblastoma: to GAGE or not to GAGE. Oncol Res 14(6):291-295
38. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. 2002. Regulation of the IRF-1 tumour modifi er during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21(51):7776-7785
39. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 5(5):375-386
40. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H, Jochum W. 2009. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 124:352-357
41. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. 2002. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 22(1):39-47
42. Sato M, Taniguchi T, Tanaka N. 2001. The interferon system and interferon regulatory factor transcription factors-studies from gene knockout mice. Cytokine Growth Factor Rev 12(2-3):133-142
43. Sharf R, Meraro D, Azriel A, Thornton AM, Ozato K, Petricoin EF, Larner AC, Schaper F, Hauser H, Levi BZ. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem 272(15):9785-9792
44. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. 2006. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442-5447
45. Stang MT, Armstrong MJ, Watson GA, Sung KY, Liu Y, Ren B, Yim JH. 2007. Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells. Oncogene 26(44):6420-6430
46. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. 1999. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 39(4):298-304
47. Takaoka A, Tamura T, Taniguchi T. 2008. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 99(3):467-478
48. Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535-584
49. Tanaka N, Ishihara M, Taniguchi T. 1994. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 83(1-2):191-196
50. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655
51. Taniguchi T, Tanaka N, Ogasawara K, Taki S, Sato M, Takaoka A. 1999. Transcription factor IRF-1 and its family members in the regulation of host defense. Cold Spring Harb Symp Quant Biol 64:465-472
52. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182(3):689-698
53. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643-1647
54. Wang Y, Liu DP, Chen PP, Koeffl er HP, Tong XJ, Xie D. 2007. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 67(6):2535-2543
55. Watanabe N, Sakakibara J, Hovanessian AG, Taniguchi T, Fujita T. 1991. Activation of IFN-beta element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res 19(16):4421-4428
56. Wu GS, Saftig P, Peters C, El-Deiry WS. 1998. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16(17):2177-2183
57. Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, Fu J, Lai PB. 2007. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 96(3):477-484